retatrutide for diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide Phase 2: Type 2

Some of these symptoms overlap with GLP-1 fatigue and semaglutide fatigue , making it important to distinguish between drug side effects and genuine nutritional deficiency

How might this medication interact with other drugs I take

Both groups were following diet and exercise guidance throughout, so its hard to separate the supplements effect from the lifestyle changesand with only 30 people per group, the findings are promising but far from definitive

Retatrutide promises to help the bodys metabolism work better

Yazhou Li, Drug Design & Development Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Many users notice reduced appetite within the first 13 weeks